Flora Growth Corp. announced on Wednesday a new agreement with Blossom Genetics, a London-based company, to supply medical cannabis to the German market.
As part of the deal, two cannabis flower strains—Chemmy Jones and Northern Lights—will be introduced to Germany. The country implemented a significant recreational cannabis law on April 1, which decriminalized cannabis, allowed home cultivation, and established nonprofit “cultivation social clubs” for adult use.
Clifford Starke, Chairman and Chief Executive Officer, commented, “This supply agreement with Blossom Genetics is a pivotal step in our efforts to expand Flora’s global presence and provide top-tier cannabis products to Germany. The demand for medical cannabis has surged since legalization, and we are confident that the strains we will bring to the market, will resonate with patients and healthcare providers alike.”
Flora’s subsidiaries have operated in Germany since 2017, securing the first medical cannabis license and conducting initial sales. The company, certified by the European Union-Good Manufacturing Practice (EU-GMP), distributes cannabis products to over 1,200 pharmacies across the country.
Product deliveries are expected to begin in the fourth quarter.
